Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection

Khalid M Dousa, Ahmed Babiker, Daniel Van Aartsen, Neel Shah, Robert A. Bonomo, John L. Johnson, Marion Skalweit

Open Forum Infectious Diseases · 2018 · 18 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

Abstract Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of B-cell malignancies. There is growing concern about the risk of opportunistic infections following ibrutinib therapy. Herein, we describe the first case of Mycobacterium chelonae skin and soft tissue infection in a patient receiving ibrutinib and recount the challenges in treating this infection.

References

8